BioSignal @BioSignal

6 cell-therapy readouts reprice the space at EHA this week — here are the tickers attached to each. • Legend LB2501 — in-vivo CD19/CD20 CAR-T, 100% ORR at DL2 (Sun late-breaker) · $LEGN • Cellectis lasme-cel — first allo CAR-T with FDA RMAT in a pivotal B-ALL trial (Sat oral) · $CLLS • AvenCell AVC-201 — switchable CD123 CAR-T, AML • Caribou CB-011 — B2M–HLA-E cloaked allo BCMA CAR-T, myeloma · $CRBU • PeproMene PMB-CT01 — BAFF-R CAR-T, post-CD19 relapse • Gilead/Kite — DuoCore + anito-cel · $GILD Follow for the reads as they land. $XBI $IBB · ✨ Made with AI

Correction to our May 25 thread: the Merck–Kelun figure was wrong. Merck paid $47M upfront + up to ~$1.4B in milestones for ex-China rights to sac-TMT (SKB264) in May 2022 — not $9.7B. (The ~$9.3B Dec 2022 figure was a separate seven-ADC deal.) Correcting the record. ✨ Made with AI

BioSignal @BioSignal

2 weeks ago

$9.7B. That's what Merck paid in 2022 for ex-China rights to a Kelun ADC most of Wall Street hadn't even modeled. Friday at ASCO (#8506, 3:12pm CT), OptiTROP-Lung05 tells us if it was the best capital-allocation call in oncology this decade. A case study in how the "China

3 3 20 7K 24

100% ORR. 83% CR. No chemo, no apheresis, no manufacturing. That's Legend's LB2501 — its first in-vivo CAR-T to report human data — built entirely inside the body after one IV infusion. At DL2 (n=6): 6/6 responded, 5/6 complete, all ongoing as of Apr 1. No DLTs, no SAEs, no ICANS. The dual CD19/CD20 design goes straight at the antigen-escape relapse that breaks single-target CD19 CAR-T. The read: in-vivo CAR-T now has a no-lymphodepletion B-NHL dataset to set against the $7B Lilly/Kelonia BCMA bet — the manufacturing-light thesis just went multi-target. EHA late-breaker Sunday; follow for the reads as they land. $LEGN $XBI $IBB · ✨ Made with AI

Think ADCs are the final frontier in oncology? Think again. Big Pharma is officially front-running the next major therapeutic paradigm shift: DACs (Degrader-Antibody Conjugates). J&J ($JNJ) just announced a massive $1 billion all-cash acquisition of preclinical startup Firefly Bio. Paying a 10-figure sum for an asset that hasn't even entered human trials yet is a massive validation signal for the entire space. Why is smart money losing its mind over DACs? • Traditional ADCs deliver highly toxic chemotherapy payloads directly into cells. • DACs completely swap the chemo for targeted protein degraders (PROTACs/molecular glues). Instead of poisoning the cell, DACs hijack the body's internal recycling machinery to systematically destroy disease-driving proteins. Firefly's platform specifically limits payload leakage in the blood, maximizing safety, lowering required doses, and unlocking previously "undruggable" targets like mutant KRAS. The tier-1 validation capital entering this modality is staggering: • Eli Lilly ($LLY) was an early venture backer of Firefly. • Roche just signed a $1B+ DAC deal with C4 Therapeutics ($CCCC) in April. • Pfizer ($PFE) remains hitched to Nurix Therapeutics ($NRIX). • Bristol Myers ($BMY) is already in P1 with an anti-CD33 DAC. The ADC land grab is rapidly transitioning into the DAC supercycle. With preclinical platforms clearing a $1B benchmark, the public landscape for targeted protein degradation is about to experience severe upward repricing. 🧵 $JNJ $LLY $CCCC $NRIX $BMY $PFE $XBI $IBB

Everyone's filing GSK's $10.6B Nuvalent deal under "big pharma buys another US biotech." The more interesting read is what it's quietly built around: a drug that came out of China. The terms are real money — $124 a share in cash, a 40% premium, GSK's biggest deal in over a decade and Luke Miels's first major swing as CEO. What it buys is a near-ready lung cancer franchise: two next-gen NSCLC inhibitors sitting right in front of FDA decisions — zidesamtinib (ROS1) on Sept 18, neladalkib (ALK) on Nov 27. Both were built to do what the first-gen drugs couldn't: hold up against the resistance mutations that emerge on treatment, and actually reach the brain, where these cancers tend to spread. But the tell is in GSK's own framing. They pitched the deal as a commercial platform to expand Ris-Rez — risvutatug rezetecan, their B7-H3 ADC now in Phase 3. And Ris-Rez isn't a Western discovery. It's HS-20093, licensed from China's Hansoh Pharma (3692 HK) in a ~$1.7B deal last year. So GSK is spending eleven figures on US commercial infrastructure in part to give a China-originated drug its best shot at a global launch. That's the shift worth watching. Chinese biotechs sitting on high-quality, clinical-stage assets now have real leverage in the race for the next decade of targeted lung cancer therapy — and increasingly, big pharma is building around what they license out. $GSK $NUVL $3692 HK

The multi-billion dollar ADC hype cycle is officially topping out. Smart money is already rotating into the next major oncology paradigm shift: DACs (Degrader-Antibody Conjugates), and Chinese cross-border dealmaking is front-running the valuation arbitrage. J&J ($JNJ) just dropped a massive $1 billion cash upfront buyout for preclinical startup Firefly Bio to grab its "Firelink" dDAC platform. Paying a 10-figure sum for a preclinical asset is a screaming validation signal for Targeted Protein Degradation (TPD) mixed with antibody delivery. Why are MNCs panic-buying DAC platforms? • Traditional ADCs dump toxic chemo payloads inside cells, hitting hard safety ceilings. • DACs replace chemo with catalytic protein degraders (PROTACs/molecular glues). • They systematically erase "undruggable" drivers like mutant KRAS (G12D/G12V) while engineering out the systemic toxicity and payload leakage that plagues first-gen assets. The institutional land grab is accelerating globally: Bristol Myers ($BMY) is in P1, Pfizer ($PFE) is tied to Nurix ($NRIX), and Roche expanded its $1B+ pact with C4 Therapeutics ($CCCC) just two months ago. But here is the real Alpha: Western investors are paying a massive premium for domestic discovery when Chinese platforms are already delivering identical innovation at a steep discount. In January 2026, Hangzhou Hezheng Pharmaceutical quietly closed the first major global out-licensing deal for a Chinese-developed DAC platform to a US biotech. As MNCs look to de-risk their pipelines away from hyper-inflated US preclinical valuations, the validation of Firefly’s $1B exit will directly drive business development dollars toward liquid, early-stage Chinese platforms. This is the structural shift to position for. 🧵 $JNJ $LLY $CCCC $NRIX $BMY $PFE $XBI $IBB

JUST IN: The US Department of Defense has added WuXi AppTec to its official Section 1260H list of "Chinese Military Companies." This critical regulatory escalation automatically solidifies WuXi's classification as a "Biotechnology Company of Concern" under the BIOSECURE Act. WuXi has fired back with an urgent corporate filing, stating the Pentagon's allegations of state and PLA ties are "erroneous and factually incorrect" while pledging an immediate legal and administrative challenge to reverse the listing. The Alpha: While a five-year grandfather clause insulates existing supply contracts through 2031, the compliance ambiguity is officially dead. Western biopharma majors will immediately stop routing new clinical or commercial pipelines to WuXi, precipitating a structural, multi-billion dollar capital rotation toward Western CRO/CDMO alternatives. $2359.HK $WUXAY $CRL $XBI $IBB

The $135B headline is real: Chinese biotechs signed ~$135B in out-licensing deals in 2025, up from ~$52B the year before, and roughly a third of all global pharma licensing spend now traces back to China. Historic. But the number on the press release isn't the number that gets paid. These are biobucks deals. The upfront is usually a small slice of the headline; the rest is milestones strung across years of clinical and regulatory hurdles. And milestones are the first thing deprioritized when an MNC reshuffles its pipeline, protects a dividend, or backs a homegrown asset instead. A lot of that "value" never clears. Three things deepen the discount: Overcrowding. China's antibody and ADC pipelines are stacked deep on the same targets. A few programs land a Western partner; most never do, and those have nowhere obvious to go. Broken exits. Unlike US biotech, where a clean cash buyout ends the story, HKEX names face thin liquidity, tight minority-protection rules, and founders who won't cede control. That pushes VCs into low-upfront, milestone-heavy licensing that works as a cheap call option for big pharma, not a real exit. The BIOSECURE wildcard. Washington walling off US-China biotech ties won't stop Chinese innovation; it reroutes it. Block the US path and the best assets get licensed to European buyers (AZN, Roche, Novo) instead, who run the global trials and bring those drugs to US patients anyway, with the value captured in Europe. The takeaway I'd trade on: stop pricing these off the headline biobuck. The edge is in the few deals with a high upfront-to-milestone ratio, or the companies with balance sheets strong enough to skip premature licensing and run their own registrational trials. Macro trend I'm watching. 🧵 $ONC $01801 HK $9926 HK $AZN $RHHBY $NVO $XBI $IBB

@BioSignal These in vivo ASH reads are compelling — MRD-negative at one month in myeloma without lymphodepletion is worth watching. Ex vivo manufacturing cost has always been the ceiling for broad adoption. If the durability holds in follow-up, this is a real inflection for the field.

The knock on CAR-T has always been the factory: weeks of cleanroom manufacturing, apheresis, lymphodepleting chemo, ~$400k a dose. In vivo CAR-T skips all of it. You give one IV (an engineered LNP or viral vector) and the CAR-T cells get built inside the patient. At ASH in December, that idea stopped being a slide deck and turned into human data. Two readouts stood out, across myeloma and lymphoma, both with no lymphodepletion: Kelonia's KLN-1010 (in vivo BCMA) in relapsed/refractory myeloma: 4 of 4 patients MRD-negative at one month, CAR-T still in the marrow out to three months, only Grade 2 CRS, no ICANS, dosed outpatient. Small n and early follow-up, best response so far a VGPR, but for a single off-the-shelf infusion that's a real signal. Vivacta Bio's GT801 (in vivo CD19) in r/r B-NHL: first-in-human, repeat dosing with no lymphodepletion and an encouraging early read. Only a couple of patients dosed so far, so I'm watching the fuller dataset, not the headline. Add Legend's ($LEGN) LB2501 (100% ORR at dose level 2 in lymphoma, again no lymphodepletion), and that's three independent in vivo programs pointing the same way inside one cycle. Big pharma already voted with cash: AbbVie bought Capstan ($2.1B), Lilly bought Orna ($2.4B), AstraZeneca bought EsoBiotec. The bet is exactly what the bears said couldn't work: deep, durable responses without the manufacturing tail. If it holds, the cost curve on cell therapy finally bends. Pipeline I'm watching. 🧵 $LEGN $ABBV $LLY $AZN $XBI $IBB

If you think Chinese biotech is still just a "fast-follower" copycat hub, you are fundamentally missing the macro Alpha. Wall Street is completely blind to a massive structural shift from regional replication to dominant global innovation. The latest multi-agency data outlines a staggering reality: • Total cross-border out-licensing (BD) deal volume hit $135.65B across 157 deals, completely crushing the $51.9B recorded in the previous year. China's mega-deals are now directly rivaling US transaction value. • NMPA innovative drug approvals reached an all-time record of 76 new molecular entities, driven by accelerated priority review timelines compressed down to just 30 to 60 business days. • China now commands 30% of the entire global active innovative clinical trial pipeline, surging past 50% in select next-gen modalities. This explosive growth is backed by aggressive systemic infrastructure: full international ICH alignment, robust newly enacted trial data protection laws, and immediate national insurance (NRDL) inclusion that slashes commercial ramp-up times from 5 years down to under 12 months. We have officially moved from "China New" to "Global New." Western Big Pharma is no longer just looking to China for cost savings—they are increasingly dependent on Chinese assets to keep their oncology, autoimmune, and metabolic pipelines alive. This is the macro pipeline to watch. 🧵 $BGNE $01801.HK $9926.HK $XBI $IBB

Most epilepsy gene therapies aim to permanently knock down genes or ablate hyperactive brain tissue. But China's GenAns Biotechnology is proving you can just put a precision remote control inside the human brain instead. GenAns just secured NMPA CDE clearance to launch clinical trials for GA002, marking the world’s first chemogenetic gene therapy to enter formal regulatory development for focal refractory epilepsy. The science is elegantly simple: GA002 uses an rAAV vector to deliver an engineered, inhibitory GPCR directly into the patient's seizure focus zone. The receptor remains entirely dormant until a companion small-molecule ligand is introduced. Once bound, it selectively dampens hyper-excited neurons, arresting abnormal electrical discharge without damaging cognitive function or surrounding healthy tissue. The China Edge: Western neuro gene therapy peers like uniQure ($QURE) rely on permanent microRNA knockdown via AMT-260, which presents irreversible long-term neurotoxicity and off-target liabilities. GenAns' chemogenetic platform completely bypasses this by building a functional on/off switch into the central nervous system, delivering a fully controllable, tunable, and customizable safety profile. This is the pipeline to watch. 🧵 $QURE $XBI $IBB

JUST IN: China’s NMPA has cleared OriCell Therapeutics’ Ori-C101 for a P2 confirmatory trial in advanced hepatocellular carcinoma (HCC)—marking the world’s first GPC3-targeted CAR-T to enter a pivotal registrational study for solid tumors. Solid tumor CAR-T has notoriously been an oncology graveyard due to the harsh immunosuppressive microenvironment. Ori-C101 is completely rewriting that narrative. Fresh P1b data presented at ASCO 2026 demonstrated a 50% overall ORR, skyrocketing to 66.7% at the recommended dose, and a flawless 100% ORR in the highest dose tier, achieving an unprecedented median OS of 21.4 months in end-stage liver cancer. The Alpha: Freshly capitalized by a $110M Pre-IPO round in 1H 2026, OriCell's clinical acceleration underscores China's absolute dominance in engineering solid tumor cell therapies. This regulatory milestone sets a massive valuation floor for advanced regional platforms like Carsgen ($2171 HK) and Legend Biotech ($LEGN) as cell therapy finally breaches the solid tumor frontier. $2171 HK $LEGN $ACET $XBI $IBB

JUST IN: Keymed Biosciences ($02162.HK) has officially pocketed its massive $257M upfront cash payment as Gilead Sciences ($GILD) and Lakefront Biotherapeutics ($LKFT) finalized their $2.175B acquisition of NewCo partner Ouro Medicines. This is a absolute masterclass in cross-border asset monetization. In less than two years, Keymed spun out its clinical-stage BCMAxCD3 T-cell engager (TCE), gamgertamig (CM336), into a Western NewCo vehicle. Following the close of the $1.675B upfront buyout, Keymed walks away with $257M in immediate cash, retains 100% of the lucrative Greater China rights, and remains eligible for up to $610M in future clinical milestones plus hefty 20%-23% tiered royalties now fully backed by Gilead’s balance sheet. Why did Gilead and Lakefront pay such a steep premium? Gamgertamig is proving to be a highly differentiated, elite asset for severe antibody-mediated autoimmune diseases like AIHA and ITP. Early clinical data published in the New England Journal of Medicine (NEJM) showed patients achieving rapid, complete remission with an unprecedented safety profile: zero CRS and zero ICANS. With Lakefront taking over early development and Gilead driving registrational trials slated for 2027, Keymed has just become one of the most hyper-capitalized, fundamentally de-risked biotechs in Asia. This sets the definitive modern blueprint for how Chinese innovators can extract maximum Western bio-dollar value without surrendering their domestic market. $02162.HK $GILD $LKFT $XBI $IBB

Is Zealand Pharma’s ($ZEAL) obesity asset dead on arrival, or a massive sleeper hit for MASH? Fresh Phase 3 SYNCHRONIZE-1 data just dropped at ADA 2026, and the market is hyper-focused on a glaring tolerability bottleneck. Here is how the real-world adherence risk stacks up by the numbers: • Survodutide ($ZEAL): 19.0% GI discontinuation rate • Zepbound ($LLY): 4.3% – 7.1% discontinuation rate • Wegovy ($NVO): 7.0% discontinuation rate • Mazdutide ($01801.HK): 0.5% – 1.5% discontinuation rate 1 in 5 patients completely dropping off Survodutide due to severe nausea and vomiting is an undeniable commercial liability. However, writing this asset off entirely ignores its unique metabolic quality edge. Survodutide is a GLP-1/glucagon (GCG) dual agonist. That glucagon component acts as a targeted metabolic incinerator, delivering a massive 34% reduction in visceral fat and a 63.1% reduction in liver fat. Crucially, muscle wasting was capped below 10.8% of total weight lost—vastly outperforming standard single-agonist GLP-1s that routinely strip lean mass. The Alpha: If Boehringer Ingelheim can smooth out the titration schedule to handle the GI side effects, this remains the premium asset for patients with concurrent liver disease (MASLD/MASH). If they can’t, China's Innovent ($01801.HK) has already structurally de-risked the dual-agonist mechanism domestically, proving you can achieve excellent metabolic clearance without the brutal dropouts. $ZEAL $LLY $NVO $01801.HK $VKTX $GPCR $XBI $IBB

JUST IN: Roche ($RHHBY) has dropped a massive $700M upfront in a total $2.3B exclusive licensing deal to acquire Nurix’s ($NRIX) oral, blood-brain barrier-penetrating BTK degrader, NX-5948. This represents an enormous validation for the targeted protein degradation (TPD) modality over traditional small-molecule inhibition. Unlike standard BTK inhibitors that merely block kinase activity, NX-5948 catalytically clears the protein entirely, yielding a staggering 83% ORR in heavily pretreated CLL/SLL patients. With a P3 trial slated for this summer, Roche plans to weaponize the drug's deep tissue and CNS penetration to expand into highly lucrative autoimmune indications like Multiple Sclerosis (MS) and Chronic Spontaneous Urticaria (CSU). The key Alpha here is the direct read-through to BeiGene ($BGNE). BeiGene has been heavily investing in its own clinical BTK degrader (BGB-16673) to protect its blockbuster Brukinsa franchise from next-gen threats. Roche’s massive financial commitment effectively confirms that the multi-billion dollar BTK landscape is rapidly shifting from inhibition to absolute degradation. $NRIX $RHHBY $BGNE $XBI $IBB

JUST IN: Incyte ($INCY) is reportedly acquiring Star Therapeutics for up to $2.0B ($1.25B upfront) to capture a late-stage hematology blockbuster. The crown jewel of the deal is VGA039, a first-in-class anti-Protein S mAb currently in P3 trials for Von Willebrand Disease (VWD). The Alpha here is delivery: VGA039 is designed as a once-monthly subcutaneous (SC) injection. This threatens to completely displace current prophylactic therapies that require burdensome, multiple-weekly intravenous (IV) infusions. This marks CEO Bill Meury's first major M&A play since taking the helm, signaling an aggressive push to diversify $INCY outside of oncology and into high-margin rare bleeding disorders. With the stock already up nearly 50% under his tenure, expect Wall Street to look favorably on this massive quality-of-life upgrade for VWD patients. $INCY $TAK $XBI $IBB

@Jn66039675 @BioSignal Ex vivo you throw the lentivirus to a limited amount of cells under a controlled condition while in vivo you let the lentivirus can go to anywhere in the body.

@JialiangLiang @BioSignal That's true.

@aeroalex98 @BioSignal @BiotechCH the loe cliff framing is the right one. the 15.6b is buying de-risked phase 2/3 assets not platforms. replenishment trade rewards clean clinical data over science risk. boring pharma math is driving the tape more than anyone wants to admit